WAYNE, New Jersey – Friday, March 26, 2004 -- Triarco Industries, Inc. announces very encouraging results of a pilot clinical trial for their patented product Alphastat, which inhibits 5-alpha reductase. The three-month study on male patients ages 55-68 reported a 17% decrease in Prostate Specific Antigen (PSA), and a 40% decrease in dehydrotestosterone (DHT), indicating a rise in total testosterone in these subjects.
Urogenital symptoms including increased urgency to urinate, reduced urinary stream and nocturia decreased in 80% of the patients. There were two reports of increased sexual function with one report of an increase in spontaneous erections after not having experienced erections approximately 15 years.
Negative side effects of pharmaceutical treatments for elevated PSA and DHT may include hypotension, sexual dysfunction and reduced libido. There were no reports of any negative side effects in this study and no reports of any compliance issues.
We are very pleased with the results of this clinical study because it confirms the results of the pre-clinical studies and is, to our knowledge, the first natural product shown to lower PSA and DHT levels in humans.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.